Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5

doi:10.1016/j.transproceed.2013.11.084

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學系 > 期刊論文 > Item 310902500/19287

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/19287

Title:	Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5
Authors:	MJ, Wu CH, Chang CY, Cheng KH, Shu CH, Chen CH, Cheng TM, Yu YW, Chuang ST, Huang SF, Tsai HC, Ho JR, Li YN, Shiu YC, Fu
Contributors:	中山醫學大學
Date:	2014
Issue Date:	2018-06-22T04:36:28Z (UTC)
Publisher:	Transplant Proc
ISSN:	0041-1345
Abstract:	BACKGROUND: Our previous study results indicated that conversion from twice-daily Prograf to once-daily Advagraf associated with lower variability of tacrolimus blood trough level. Some factors, such as frequency of interaction by food exposure, expression of cytochrome P450 3A5 genetic polymorphism, and other interactions of unknown factors, could be the reasons for the change of variability. We aimed to clarify the impact of cytochrome P450 3A5 genetic polymorphism on the variability of tacrolimus blood trough level in Taiwanese kidney transplant recipients. METHODS: We collected blood samples from kidney transplant recipients to prepare DNA and then performed single-nucleotide polymorphism genotyping by using the restriction fragment length polymorphism. RESULTS: We found that 79 (52.7%) of 150 kidney transplant recipients had the low-expressive genotype (CYP3A53/3), whereas the other 71 (47.3%) kidney transplant recipients had high-expressive genotype (CYP3A51/1 and CYP3A51/3). The prevalence of high-expressive genotype is higher than previous reports from western countries. Compared with the patients with high-expressive genotype, the average dose-normalized trough level of tacrolimus was significantly higher in patients with low-expressive genotype. Interestingly, when patients converted from twice-daily Prograf to once-daily Advagraf, the percent coefficient of variation of tacrolimus trough level was significantly decreased in patients with high-expressive genotype. CONCLUSION: This study suggested that there is a potential benefit for kidney transplant recipients with cytochrome P450 3A5 high-expressive genotype (1/1 or 1/3) to convert from Prograf to once-daily Advagraf.
URI:	http://dx.doi.org/10.1016/j.transproceed.2013.11.084 https://ir.csmu.edu.tw:8080/ir/handle/310902500/19287
Relation:	Transplant Proc. 2014;46(2):403-5
Appears in Collections:	[醫學系] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	176	View/Open

View Licence

Loading...